Hanmi Pharma. Co., Ltd.(www.hanmipharm.com) introduced its Quantum project (anti-diabetic pipeline) to investing institutions in global healthcare.
Hanmi Pharma. (CEO. LEE, Gwansun) has presented its Quantum project, pipeline of the first-in-class medicine under development in the 33rd Annual J.P. Morgan Healthcare Conference held in the United States from January 13 to January 16.
The conference was held at The Westin St. Francis hotel in San Francisco by JP Morgan (J.P. Morgan Chase & Co.), a leading global financial services firm, where more than 300 selected global healthcare companies participated.
This annual event is held at the beginning of a year, which is reckoned as the most prestigious in the global pharmaceutical and bio field. Lim Sungki, chairman of Hanmi Pharma. Co., Ltd. and Son Jiwoong, vice president of Hanmi Pharma. Co., Ltd. as well as Lee Gwansun, president of Hanmi Pharma. Co., Ltd. took part in this year’s conference.
In particular, Lee made public in person the vision of Hanmi Pharma. Co., Ltd. and twenty-four cases of its first-in-class pipelines at the Asian session (Emerging Markets Tracks) held on January 14.
He explained in detail LAPSCOVERY, Hanmi Pharma.’s unique generic technology; Quantum project, the developing first-in-class for diabetes; HM61713, the 3rd generation of targeted agent and HM71224, medicine for rheumatoid arthritis.
In addition, Lee introduced Hanmi Pharma.’s business strategies as follows: 1) Focusing on research and development of enhanced, compounded and innovative medicine ; 2) Establishing a business model through multinational pharmaceutical companies like MSD US, Sanofi ; 3) Reflecting the successful example of Hanmi Pharma in Beijing(北京韩美药品有限公司).
Along with this presentation, Hanmi Pharma. Co., Ltd. had about forty business meetings with global healthcare companies and investors to seek an opportunity of advancing into the global market with its R&D pipeline.
“I feel thrilled that I could introduce Hanmi Pharma.’s first-in-class medicines in the prestigious healthcare conference with global leaders in the bio-pharmaceutical industry, “Lee said, “This was a chance that Hanmi Pharma.’s innovative technology in new bio and anticancer drugs can be recognized around the world again”
